Weekly Investment Analysts’ Ratings Updates for Myriad Genetics (MYGN)

Posted by Trevor Kearing on Dec 17th, 2024

Myriad Genetics (NASDAQ: MYGN) recently received a number of ratings updates from brokerages and research firms:

12/13/2024 – Myriad Genetics had its price target lowered by analysts at Bank of America Co. from $15.00 to $13.00. They now have an “underperform” rating on the stock.
12/10/2024 – Myriad Genetics is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $18.00 price target on the stock.
12/9/2024 – Myriad Genetics was downgraded by analysts at Leerink Partners from an “outperform” rating to a “market perform” rating. They now have a $21.00 price target on the stock, down previously from $30.00.
12/9/2024 – Myriad Genetics was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
11/20/2024 – Myriad Genetics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
11/18/2024 – Myriad Genetics had its price target lowered by analysts at Morgan Stanley from $32.00 to $21.00. They now have an “equal weight” rating on the stock.
11/12/2024 – Myriad Genetics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
11/11/2024 – Myriad Genetics had its price target lowered by analysts at Piper Sandler from $30.00 to $24.00. They now have a “neutral” rating on the stock.

Myriad Genetics Trading Down 2.1 %

Myriad Genetics stock traded down $0.30 during trading on Tuesday, hitting $13.82. The company had a trading volume of 646,306 shares, compared to its average volume of 757,513. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -10.63 and a beta of 1.87. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. Myriad Genetics, Inc. has a 1-year low of $13.78 and a 1-year high of $29.30. The company’s 50 day simple moving average is $18.34 and its 200-day simple moving average is $23.45.

Insider Buying and Selling at Myriad Genetics

In other Myriad Genetics news, CEO Paul J. Diaz sold 15,000 shares of the firm’s stock in a transaction on Friday, October 11th. The stock was sold at an average price of $22.93, for a total transaction of $343,950.00. Following the completion of the transaction, the chief executive officer now owns 962,378 shares of the company’s stock, valued at approximately $22,067,327.54. This trade represents a 1.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 2.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Myriad Genetics

A number of large investors have recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in shares of Myriad Genetics by 34.1% during the third quarter. GAMMA Investing LLC now owns 1,620 shares of the company’s stock valued at $44,000 after buying an additional 412 shares in the last quarter. Atria Investments Inc grew its stake in shares of Myriad Genetics by 5.4% during the third quarter. Atria Investments Inc now owns 11,414 shares of the company’s stock worth $313,000 after purchasing an additional 581 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Myriad Genetics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock worth $87,000 after purchasing an additional 583 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Myriad Genetics by 3.4% during the second quarter. Arizona State Retirement System now owns 25,160 shares of the company’s stock worth $615,000 after acquiring an additional 829 shares during the period. Finally, Federated Hermes Inc. grew its position in Myriad Genetics by 1.5% in the second quarter. Federated Hermes Inc. now owns 56,807 shares of the company’s stock valued at $1,389,000 after purchasing an additional 846 shares in the last quarter. Institutional investors own 99.02% of the company’s stock.

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.